Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10911340 | Lung Cancer | 2012 | 18 Pages |
Abstract
⺠The diagnosis of lung cancer involves the identification and complete classification of malignancy. ⺠New therapeutic options require specific subtyping of NSCLCs and, increasingly, the identification of therapeutically predictive molecular markers, to determine the safest and most effective choice of drugs. ⺠Small diagnostic sample size and tumour complexity often prevent specific subtyping on morphological grounds alone (NSCLC-NOS). ⺠Immunohistochemistry can predict the likely NSCLC subtype (squamous cell vs. adenocarcinoma) in most NSCLC-NOS cases. ⺠Tissue sampling should be maximized whenever feasible and deemed clinically safe, reducing the need for re-biopsy for additional studies. ⺠Tissue handling, processing and sectioning should minimize wastage and optimize use of tissue for diagnosis.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Erik Thunnissen, Keith M. Kerr, Felix J.F. Herth, Sylvie Lantuejoul, Mauro Papotti, Robert C. Rintoul, Giulio Rossi, Birgit G. Skov, Birgit Weynand, Lukas Bubendorf, Grünberg Katrien, Leif Johansson, Fernando López-RÃos, Vincent Ninane,